Unbiased Analysis of Today's Healthcare Issues

Quotation of the Day: Pricing of Biosimilars

Written By: Jason Shafrin - Mar• 04•14

Bilsimilars are biologic medical products whose active drug substance is made by a living organism or derived from a living organism by means of recombinant DNA or controlled gene expression methods. Biologic drugs can be patented, but once the patents expire, biosimilars can enter the market.

Are biosimilars> priced similarly to generics? According to Ana Nicholls, healthcare analyst at The Economist Intelligence Unit, the answer is no:

“Given the lower levels of competition in the biosimilars market, the copies tend to be priced at just 20-30% below the original drugs, compared with around 90% below for traditional generics.”

You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

One Comment

  1. […] “Given the lower levels of competition in the biosimilars market, the copies tend to be priced at just 20-30% below the original drugs, compared with around 90% below for traditional generics.” (Jason Shafrin) […]

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>